Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod | Zendy

Lara Diem | Zendy; Krassen Nedeltchev | Zendy; Timo Kahles | Zendy; Lutz Achtnichts | Zendy; Oliver Findling | Zendy

Open Access

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod

Author(s) -

Lara Diem,

Krassen Nedeltchev,

Timo Kahles,

Lutz Achtnichts,

Oliver Findling

Publication year - 2018

Publication title -

therapeutic advances in neurological disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.684

H-Index - 50

eISSN - 1756-2864

pISSN - 1756-2856

DOI - 10.1177/1756286418791103

Subject(s) - natalizumab , fingolimod , medicine , multiple sclerosis , discontinuation , expanded disability status scale , progressive multifocal leukoencephalopathy , odds ratio , pediatrics , immunology

Patients remain clinically stable after discontinuing natalizumab and switching to other therapies. However, when considering NEDA-3 criteria, a considerable proportion of patients show disease reactivation. Careful monitoring and early evaluation of alternatives is necessary after switching from natalizumab to other treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research